Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

NCT01631214 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

4093

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Women With Osteoporosis

Interventions

BIOLOGICAL: Romosozumab
DRUG: Alendronate
DRUG: Placebo to Romosozumab
DRUG: Placebo to Alendronate

Sponsor

Amgen